Phase 2 Lung Cancer Trial, Recruiting NCT06262321 Sponsor: University of Rochester Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06262321
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a type of lung cancer called Non-Small Cell Lung Cancer (NSCLC) that does not have certain specific genetic mutations (such as EGFR, ALK, or ROS1)
  • Your cancer is at an advanced (Stage IV) level, or your earlier-stage lung cancer has come back after treatment that was meant to cure it
  • You have not had radiation therapy to the chest area before
  • You have tumors in the chest (lungs and/or nearby lymph nodes) that could be treated with radiation therapy aimed at reducing symptoms
  • Your cancer meets at least one "high-risk" feature, such as a large tumor (5 cm or more) not near the centre of the chest, or tumors close to important structures like the airway, esophagus, spine, heart, or major blood vessels
  • You may have already received other cancer treatments (such as chemotherapy or immunotherapy), as long as you are enrolled within 6 months of starting treatment for Stage IV disease
  • You are allowed to receive immunotherapy at the same time as the radiation treatment in this trial
  • You have had, or are having, radiation to areas outside the chest (such as bones or the brain) for other cancer-related reasons

Who may not be able to join:

  • You have previously had radiation therapy to the chest area
  • You have an active autoimmune condition such as lupus or Sjögren's disease
  • Your lung cancer is causing severe symptoms (such as a blocked airway, a blood clot blocking a major vein, coughing up large amounts of blood, spinal cord compression, or nerve problems in the arm) that need urgent radiation treatment for reasons other than bone pain
  • Your general health and ability to carry out daily activities is significantly limited (confirm with trial site what score applies to you)
  • You have cancer that has spread to the brain in a way that cannot be treated with immunotherapy alone, surgery, or targeted radiation — for example, if you need whole-brain radiation therapy
  • You have a significant build-up of fluid around the lung that is clearly caused by cancer spreading across the lining of the lung (note: if you have fluid but no visible signs of cancer on the lining, you may still be eligible — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
15 May 2024
Est. completion
1 February 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Freedom from symptomatic progression of irradiated thoracic target(s)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov